Expert panelists discuss insights on HER2+ BC from the 2022 ASCO Annual Meeting including safety updates from DESTINY-BREAST03, data on the potential prognostic value of TILs, and trials on local therapy for oligometastatic disease.
A panel of experts examines the challenges associated with treating leptomeningeal metastases in patients with HER2+ mBC including difficulties with using intrathecal chemotherapy and radiation therapy.
Rita Nanda, MD, reflects on the use of systemic treatment with tucatinib in patients with visceral and CNS disease, and Ryan Jones, MD, discusses the evolving role of concurrent systemic therapy with radiosurgery.
Highlighting the clinical scenario of a 29-year-old woman with breast cancer, Tiffany Traina, MD, leads a discussion on challenges associated with accurate biomarker testing, tumor heterogeneity, and repeat biopsies.
Ryan Jones, MD, reflects on factors to consider when selecting stereotactic radiosurgery vs whole-brain radiotherapy including performance status, extracranial control, number of lesions, and CNS progression.